Research programme: neurological disorders - Weizmann Institute of Science/ Health Research Institute of Santiago de Compostela

Drug Profile

Research programme: neurological disorders - Weizmann Institute of Science/ Health Research Institute of Santiago de Compostela

Latest Information Update: 19 Jan 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Weizmann Institute of Science
  • Class Enzymes
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Glioblastoma; Stroke

Most Recent Events

  • 10 Dec 2015 Weizmann Institute of Science, Health Research Institute of Santiago de Compostela and Sun Pharma agree to co-develop therapies for the treatment of neurological diseases like brain stroke and glioblastom
  • 10 Dec 2015 Preclinical trials in Glioblastoma in Israel (unspecified route)
  • 10 Dec 2015 Preclinical trials in Stroke in Israel (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top